Trial Profile
A prospective study to evaluate the efficacy and safety of tolvaptan in preventing acute kidney injury in the ICU patients with severely decompensated acute heart failure (AHF).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Dec 2015
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary) ; Furosemide
- Indications Acute kidney injury; Decompensated heart failure; Heart failure
- Focus Therapeutic Use
- 09 Dec 2015 New trial record